- Home
- MYN vs IMRX Comparison
MYN vs IMRX Comparison
Compare MYN & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYN | IMRX |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.9M | 313.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MYN | IMRX |
|---|---|---|
| Price | $9.59 | $5.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 165.5K | ★ 618.4K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.40 | $3.86 |
| 52 Week High | $10.26 | $10.08 |
Technical Indicators
Market Signals| Indicator | MYN | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 53.03 |
| Support Level | $9.45 | $4.82 |
| Resistance Level | $9.95 | $5.32 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 15.79 | 36.51 |
Price Performance
Historical ComparisonAbout MYN Blackrock MuniYield New York Quality Fund Inc.
BLACKROCK MUNIYIELD N Y QUALITY FD INC is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.